Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, phase 2 study of biweekly Velcade [bortezomib] and intermittent Caelyx [doxorubicin-liposomal] in patients with ovarian cancer failing platinum containing regimens

Next Previous
Trial Profile

An open label, phase 2 study of biweekly Velcade [bortezomib] and intermittent Caelyx [doxorubicin-liposomal] in patients with ovarian cancer failing platinum containing regimens

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Doxorubicin liposomal
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Sponsors Takeda Oncology

Most Recent Events

  • 15 Jul 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
  • 05 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
  • 15 Mar 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top